SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (7287)9/23/1998 2:00:00 PM
From: Arthur Radley  Read Replies (1) | Respond to of 17367
 
I agree that we will see more deals involving biotechs. If you think about it...numerous bio's now have products in the critical Phase III's, they are not affected by the foreign markets and exchange rates, demographics are ever increasing for the need of newer drugs, therefore, now is the time for the BIG DRUG companies to step to the plate with their cash hordes. I wonder if I'm saying this only because I own LGND, TTNP, XOMA, AORI, PM and LIFC.(:>)



To: aknahow who wrote (7287)9/24/1998 8:51:00 AM
From: Robert K.  Read Replies (1) | Respond to of 17367
 
Of further interest. Toxoplasmosis and AIDS...........................>>>>>>
>>>http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9571741&form=6&db=m&Dopt=b

It is a old data (so a grain of salt is in order)
But as I read it here, I see
>Toxoplasmosis in 10% of AIDS cases as major cause.
>9 month survival time (big grain of salt here) (improved treatments)

Any expert opinions/comments?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News